The first batch of a homemade Iranian COVID-19 vaccine, dubbed COVIran Barekat, comprising 300,000 doses, was unveiled in a ceremony in the northern province of Alborz on Tuesday.
The jab is Iran’s first COVID-19 vaccine whose mass production has started, tabnak.ir reported.
The unveiling ceremony was attended by Mohammad Mokhber, the head of the Execution of Imam Khomeini’s Order (EIKO), and President of Iran’s Food and Drug Administration (FDA) Mohammadreza Shanehsaz.
The first batch of the vaccine is expected to be delivered to the Iranian Health Ministry.
In an address to the ceremony, Mokhber said the site launched for the production of the jab will become the region’s biggest vaccine producer.
He added the plant is capable of producing DNA and subunit vaccines.
The EIKO chief gave the assurance that the factory will hand over one million doses of its vaccine to the Health Ministry within a few days, adding the figure will reach at least 30 million doses by late September.
He said that the first and second phases of the jab’s clinical trial were completed successfully, adding the third phase is underway in six cities.
Speaking at the same event, Shanehsaz, who is also a deputy health minister, described as a major achievement the start of the vaccine’s mass production by EIKO.
He estimated that the country’s COVID-19 vaccine production capacity would reach 197 million doses within a year, saying it would be a miracle.
Speaking to IRNA on Tuesday, Reza Mazhari, the executive manager of the project to develop COVIran Barekat vaccine, said after completing the semi-industrial phase of the plan, the mass production phase started.
An industrial production line to this end was set up, he noted, adding another line is being established.
After the production lines become operational by September 22, the group will be able to supply 20 million doses of the vaccine to the market per month.
The first phase of the clinical trial of the jab began in late December 2020 in a ceremony attended by Health Minister Saeed Namaki. The second phase, vaccinating 280 volunteers, started in March. The third phase kicked off in late April.
Soberana 2 third phase
In addition, the third clinical trial phase of a COVID-19 vaccine being jointly developed by Iran and Cuba began on Tuesday in the northern Iranian province of Mazandaran.
Four volunteers received the jab as part of the third phase. Named Soberana 2, the vaccine is being developed by Iran’s Pasteur Institute and Cuba’s Finlay Vaccine Institute.